PDX Portal

Model Details

Patient Information for Model: HCI-009

Model Contact

Model: HCI-009
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: HCI-009

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

There are no omics data for this model.

Drug Studies for Model: HCI-009

Treatment Response Across All Studies

CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA

Drug Study: T104-T109

Study Metadata

Study ID: T104-T109
Study Type: Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms: 2
Mouse Strain:

PI: Alana Welm
Study Title: Birinapant Efficacy Study
Treatments: Birinapant
Study Duration:
Transplant Site
Transplant Material:

Study Design

Study Description	Arm Type	Treatment Arms	Number of Mice	Dose (mg/kg)	Concentration (mg/ml)	Vehicle	Route	Dosing Schedule
	Treatment	Birinapant		20
	Control	Vehicle

Treatment Results

Treatment Arm	Treatment Duration	Monitoring Method	Monitor Duration	Tumor volume over time (%)	Response Category
Birinapant			39	1892	PD
Vehicle			39	2877	PD

Histology Information for Model: HCI-009

There are no histology images for this model.

Metastasis Information for Model: HCI-009

Patient

PDX

Abdomen

Adrenal gland

Bone

Bone (de novo)

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

LMD

Liver

Lung

Lymph node

Lymph nodes

Neck

None

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

medistinal and right hilar

Patient Treatment Information for Model: HCI-009

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Reason Stopped
10	Radiation Therapy	Neoadjuvant	42.08	42.16	29 days
15	Cyclophosphamide, Methotrexate, 5-Fluorouracil	Neoadjuvant	42.25	42.41	58 days	Progressive disease
20	Tamoxifen, Anastrozole	Neoadjuvant	44.08	65.08	7665 days	Progressive disease
25	Radiation Hip	Neoadjuvant	64.0	64.08	29 days	Progressive disease
30	Paclitaxel	Neoadjuvant	65.08	65.16	29 days	Progressive disease
35	Zolendronic Acid	Neoadjuvant	65.25	65.33	29 days	Progressive disease
40	Fulvestrant	Neoadjuvant	65.41	65.5	33 days	Progressive disease
45	Alternative Medicine	Neoadjuvant	65.67	65.91	88 days	Progressive disease	Patient Died